<DOC>
	<DOCNO>NCT01356329</DOCNO>
	<brief_summary>Prophylactic treatment start surgery patient discharge hospital ( 18 ) . Then patient 2 follow visit gyne- oncology clinic . The first visit 2 week discharge &amp; second visit 3 month surgery . In visit patient evaluate evidence thrombo-embolic event clinically &amp; radiologically need ( spiral CT , V/Q scan &amp; low limp Doppler ) . Any side effect adverse reaction report &amp; evaluate related drug use .</brief_summary>
	<brief_title>Efficacy Safety LovenoxTM ( Enoxaparin ) Versus HeparinTM Gynecologic Oncology Patients</brief_title>
	<detailed_description>This study phase IIIB , randomize , open label , non-comparative control trial , prospectively enrol 150 female assess efficacy safety Enoxaparin ( Group A ) Unfractionated Heparin ( Group B ) Gynecologic Oncology Patients In Kingdom Saudi Arabia require surgery admission prevention VTE . Patients meet Inclusion Criteria sign inform consent randomly assign 1 2 treatment group ( Group A Group B ) . Subjects assign consecutive study number accord predetermined random code generate Biostatistician . The randomisation base 1:1 ratio .</detailed_description>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Cancer patient age 18 year older admit diagnosis malignancy suspension malignancy go major surgery . 2 . Patient follow condition : 1 . Any patient admit diagnosis Gynecologic malignancy &amp; go major surgery laparotomy &amp; abdominal hysterectomy OR 2 . All stag laparotomy do suspected ovarian malignancy either ultrasound finding tumor marker ( raise CA 125 ) &amp; find either borderline benign ovarian tumor 3 . Signed Informed Consent Form 1 Renal failure assess serum creatinine &gt; 2.0mg/dL ( 180 mmol/L ) 2 . Patients anticoagulant treatment previous 6 month 3 . Bleeding disorder platelet count &lt; 80x109/L 4 . Known hypersensitivity unfractionated heparin LMWHs 5 . Pregnant woman 6 . Obese patient body mass index â‰¥ 47</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Gynecologic malignancy , major surgery</keyword>
</DOC>